AlphAIAlphAI — Financial news for AI agents
investing.com$RUM

RUM, SLS, and ADMA: three undercovered mid-cap picks

Investing.com highlights three mid-cap stocks with low analyst coverage: Rumble (RUM) signed a $13.7B GPU deal, Sellas Life Sciences (SLS) rose 683% in a year, and ADMA Biologics (ADMA) trades at 13.7x earnings after a 44% pullback. RUM's Q2 revenue was $40.4M, up 61% YoY, with Q3 guidance of $87-93M. SLS has a 'Great' health score, while ADMA is profitable and shows early signs of stabilization.

Original reporting
investing.com
Published Aug 25, 2026, 2:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 2:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$RUM
Bullish
high confidence
Mentioned
$RUM · $SLS · $ADMA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RUMBullishHigh
01

Why it matters

The article surfaces a material contract for Rumble and underscores valuation anomalies in SLS and ADMA.

02

Market read

The GPU contract could re‑rate Rumble, while SLS and ADMA present speculative and value plays respectively.

03

What to watch

Liquidity constraints and limited analyst coverage may cause higher volatility for all three mids.

Relevance 8/10Novelty 8/10Timing: recently announced contract

Background

Mid‑cap stocks with low analyst coverage are being highlighted as potential hidden opportunities.

Company-level read

Ticker impact

$RUMBullishHigh confidence
Context

Rumble announced a $13.7 billion six‑year GPU services contract, its largest deal to date.

Expected impact

Potential upside as investors re‑price the AI‑compute exposure.

Evidence & confidence

Deal size and forward‑revenue guidance suggest a multi‑digit revenue run‑rate, which is material for a $3.7 B market‑cap stock.

$SLSNeutralMedium confidence
Context

Sellas Life Sciences posted a 683% YTD gain and a "Great" health rating, highlighting strong momentum.

Expected impact

Continued upside if clinical milestones are confirmed; sharp pull‑back possible on setbacks.

Evidence & confidence

Price move is driven by speculation rather than a concrete new catalyst.

$ADMABullishMedium confidence
Context

ADMA Biologics trades at a 13.7× P/E after a 44% pullback, positioning it as a rare profitable biotech.

Expected impact

Modest upside if earnings remain stable and market sentiment improves.

Evidence & confidence

Profitability at a discount is notable, but no new event drives the price.

Market effects

Sector

Highlights undervaluation of AI‑compute providers and may lift peers like CoreWeave.

Regional

U.S. AI infrastructure sector gains visibility.

Global

Large GPU contract underscores growing demand for AI compute worldwide.

Counterpoint

What could challenge this read

Rumble's valuation could be overstated if the GPU contract faces execution risk.

Key entities

  • company
    Rumble

    Video platform transitioning to AI compute services.

  • company
    Sellas Life Sciences

    Clinical‑stage biotech with strong price momentum.

  • company
    ADMA Biologics

    Profitable plasma‑derived therapeutics firm.

Read at source← All news

Related articles

$ADMAHighAI 8/10

Adma Biologics reiterates at least $530M 2026 revenue and raises minimum adjusted EBITDA to at least $275M as ASCENIV demand accelerates (NASDAQ:ADMA)

Adma Biologics (ADMA) reiterated its 2026 revenue target of at least $530M and raised its adjusted EBITDA minimum to $275M, citing accelerating demand for its ASCENIV product. CEO Adam Grossman attributed the growth to commercial momentum. The company reported these updates during its Q3 2026 earnings call.

seekingalpha.com
$SLSMedAI 8/10

SLS Stock Rises Overnight Despite Citi’s 64% Stake Cut — Retail Bulls Say SLS009 Alone Could Outvalue Sellas

Sellas Life Sciences (SLS) stock rose 0.4% overnight after Citigroup cut its stake by 64%, while retail investors highlighted the potential value of SLS009. SLS009 showed 34% response rate in a Phase 2 AML study, with higher rates in specific subtypes. Sellas also expects Phase 2 and Phase 3 trial results this quarter. SLS stock is up 142% year-to-date.

stocktwits.com
$ADMAMed

ADMA Biologics Q3 Earnings Call Highlights

ADMA Biologics reported Q3 gross profit of $99.9M, up from $75.6M YoY, with gross margin at 71%. GAAP net income rose 37% YoY to $49.9M. ASCENIV revenue is expected to grow ~25% for the full year, while BIVIGAM faced pricing pressures. The company plans to present real-world outcomes data at an upcoming conference and received constructive FDA feedback on SG-001. ADMA repurchased 16.5M shares and targets $200M in repurchases for 2026.

finance.yahoo.com
$ADMAMed

Adma Biologics: Q3 Earnings Snapshot

Adma Biologics (ADMA) reported Q3 profit of $49.9M, or 22 cents per share, with revenue of $141.1M. The company expects full-year revenue of $530M. Shares have fallen 43% YTD and 28% over the past year, closing at $10.48 on Wednesday.

finance.yahoo.com
$ADMAHigh

ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update

ADMA BIOLOGICS, INC. (ADMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update 3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Mi

SEC EDGAR 8-K
$INTCHighAI 8/10

Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In Focus

Intel (INTC) reported Q3 sales of $16.5B, up 21% YoY, and beat earnings estimates. Weak PC demand due to memory semiconductor shortages impacted results. AMZN's earnings also dragged down chipmakers like NVDA, MU, AVGO, and AMD. U.S. consumer spending rose in September with inflation at 3.6%. Geopolitical tensions in the Strait of Hormuz pushed oil prices higher. IOVA and SLS also saw significant share price declines.

finance.yahoo.com